2023
@@@@@@@@@@@
Updated on 6/6/2023
LPBI Group’s Mission #5:
Phase 1:
- Will create a Pilot Prototype for all LPBI Group’s 300 Audio Podcast: Design an Autonomous Medical Text Update System with ChatGPT
Phase 2:
- Will Scale up the Pilot for a new IT project: Autonomous Medical Text Update System for 6,170 Scientific articles in http://pharmaceuticalintelligence.com
Updated on 5/5/2023
LPBI Group will cover 2023 World Medical Innovation Forum in Real Time.
From: “Doyle, Tracy” <tdoyle5@mgb.org>
Date: Friday, May 5, 2023 at 2:35 PM
Subject: Media Invite: World Medical Innovation Forum — June 12-14, Boston
To: Aviva Lev- Ari, PhD, RN
Media Invite: World Medical Innovation Forum: Monday, June 12—Wednesday, June 14, Boston
Exploring innovation and investment in Brain Health/CNS, Oncology, and Inflammation & Immunology
Mass General Brigham, one of the nation’s leading academic medical centers, is pleased to invite media to attend the annual World Medical Innovation Forum (WMIF) Monday, June 12 – Wednesday, June 14 at the Westin Seaport in Boston. The event features expert discussions of scientific and investment trends related to three areas of medicine poised for near-term breakthroughs: brain health and central nervous system disorders (CNS), oncology, and inflammation & immunology. The agenda features nearly 175 executive speakers from healthcare, pharma, venture, start-ups, and the front lines of care, including many of Mass General Brigham’s Harvard Medical School-affiliated researchers and clinicians. Bank of America, presenting sponsor of the Forum, will provide additional insights on the investment landscape associated with these areas of healthcare innovation.
Forum highlights include:
1:1 interviews with leading CEOs and government officials including:
Robert Califf, MD, U.S. Commissioner of Food and Drugs, FDA
Sree Chaguturu, MD, CMO, CVS
Mikael Dolsten, MD, PhD, CSO, Pfizer
Anne Klibanski, MD, President and CEO, Mass General Brigham
Brian Moynihan, CEO, Bank of America
David Ricks, CEO, Eli Lilly and Company
Chris Viebacher, CEO, Biogen
Renee Wegryzn, PhD, Director, ARPA-H
Plenary Sessions – expert panels including:
- The Next Wave of Promising Psychiatry and Neurology Drugs
- The Science of Happiness
- The Innovation Gap: Emerging Modalities and Mechanisms for Treating CNS Disease
- The Biologic Revolution in Cancer
- Driving Cell Therapy into Solid Tumors
- Precision Oncology for Liquid Tumors
- Reprogramming the Immune System
- Emerging Targets in Inflammation & Immunology
- Capital Formation in Healthcare – Trends and Opportunities
Leading biotech speakers from companies including:
- Amylyx
- BioXcel
- Cognition Therapeutics
- QurAlis
- Mammoth Biosciences
- Compass Therapeutics
- Immunopharma
- Boundless Bio
- Intellia
- AlloVir
Exclusive programming:
- First Look – 16 rapid-fire presentations from leading Mass General Brigham researchers in brain health/CNS, oncology, inflammation & immunology
- The Doctor is In – A series of concurrent learning sessions presented by senior Mass General Brigham clinicians and Bank of America analysts, including a session on the impact of Boston-based biotech innovation incubators and accelerators
- Disruptive Dozen – Announcement of 12 break-through technologies likely to emerge in clinical use in the next few years
WMIF full agenda and list of speakers
Register Now:
For complimentary media registration, click the link below.
Tracy
Follow us on Twitter @MGBInnovation
Tracy M. Doyle
Marketing & Communications Director, Innovation
Mass General Brigham
399 Revolution Drive, Suite 955, Somerville, MA 02145
T 262-227-5514
tdoyle5@partners.org
innovation.partners.org
Updated on 2/14/2023
Press Release for Five Bilingual BioMed e-Series in English and in Spanish
https://pharmaceuticalintelligence.com/2023/01/29/press-release-for-five-bilingual-biomed-e-series/
Updated on 2/14/2023
2023 Update from LPBI Group
https://pharmaceuticalintelligence.com/2022/02/21/update-from-lpbi-group/
Updated on 2/12/2023
UPDATED to 1/1/2023 –>> February 1, 2021 – We Celebrate 1,924,400 e-Readers, 6,000 Scientific Journal Articles, 7,525 Scientific Comments, A Journal Ontology of 728 Medical & Life Sciences Research Categories, 10,440 Tags, Top Article 17,300 Views, Top Author 487,500 Views on PharmaceuticalIntelligence.com
Updated on 1/19/2023
Five Bilingual BioMed e-Series – 37 volumes
Curator, Book Editor & Bilingual BioMed e-Series, Editor-in-Chief:
Aviva Lev-Ari, PhD, RN
- English Edition: 18 volumes in 17 books, and
- Spanish Edition (EDICIÓN EN ESPAÑOL): 19 volumes in 19 books
https://pharmaceuticalintelligence.com/five-bilingual-biomed-e-series/
Updated on 12/31/2022
We are VERY proud to have been successful in publishing our
Spanish Edition: Series A, B, C, D in 2022
Series E in the 1st week in 1/2023
LPBI GROUP IS PUBLISHER
on Kindle Edition of
37 e-Books in Medicine and Life Sciences
- All by our Team members
- All books with one Editor-in-Chief
- All contents “Invented here”
Serie A
Serie A: libros electrónicos acerca de las enfermedades cardiovasculares
For the Series in Spanish Audio ($385) go to
https://www.amazon.com/gp/product/B0BPR9L1ZX?ref_=dbs_p_pwh_rwt_anx_a_lnk
Spanish Series B
Fronteras de la investigación genómica
(3 book series) Kindle Edition
For the Series in Spanish Audio ($305) go to
https://www.amazon.com/dp/B0BQGZYZVT?binding=kindle_edition&ref=dbs_dp_rwt_sb_pc_tukn
Volume 3: Text Analysis Results of NLP [Madison Davis]
Spanish Series C
Serie C: libros electrónicos acerca del cáncer y la oncología
(2 book series) Kindle Edition
For the Series in Spanish Audio ($231) go to
https://www.amazon.com/dp/B0BQHMRK3C?binding=kindle_edition&ref=dbs_dp_rwt_sb_pc_tukn
Cancer Volume 1: Text Analysis Results of NLP [Madison Davis] – PART B
Serie D:
Libros electrónicos de Biomedicina. Metabolómica, inmunología, enfermedades infecciosas, genómica reproductiva y endocr
(4 book series) Kindle Edition
For the Series in Spanish Audio ($268) go to
https://www.amazon.com/dp/B0BR8P5TST
Spanish Series E
Serie E: Medicina centrada en el paciente
(4 book series) Kindle Edition
For the Series in Spanish Audio ($217) go to
https://www.amazon.com/dp/B0BRGMCM8Q?binding=kindle_edition&ref=dbs_dp_rwt_sb_pc_tukn
ADD Series Image
UPDATED on 12/30/2022
New Genre Series B
For citation: of LPBI Group’s Genomics Volume 3 in New Genre Edition
Results of Medical Text Analysis with Natural Language Processing (NLP): Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS
https://www.amazon.com/dp/B0BRD8JXTL
Results of Medical Text Analysis with Natural Language Processing (NLP): Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, … de la investigación genómica Book 3) Kindle Edition
by Madison Davis (Author), Aviva Lev-Ari (Editor), Stephen J. Williams (Editor), Marcus W. Feldman (Editor) Format: Kindle Edition
Serie B: Fronteras de la investigación genómica
(3 book series) Kindle Edition
by Larry H. Bernstein (Author) , Stephen J. Williams (Author) , Sudipta Saha (Author) , Ritu Saxena (Author) , Tilda Barliya (Author) , Anamika Sarkar (Author) , Marcus W. Feldman (Author) , Demet Sag (Author) , Prabodh kandala (Author) , Larry H. Bernstein (Author) , Aviva Lev-Ari (Author) , Madison Davis (Author)
https://www.amazon.com/dp/B0BQGZYZVT?binding=kindle_edition&ref=dbs_dp_rwt_sb_pc_tukn
UPDATED on 12/28/2022
View on Amazon.com
Serie D:
Libros electrónicos de Biomedicina. Metabolómica, inmunología, enfermedades infecciosas, genómica reproductiva y endocr
(4 book series) Kindle Edition
Series URL
https://www.amazon.com/dp/B0BR8P5TST
Volume Titles & URL on Amazon.com
Volumen 1
(Spanish Edition) Kindle Edition
http://www.amazon.com/dp/B0BR8DPPZW
Volumen 2
(Spanish Edition) Kindle Edition
http://www.amazon.com/dp/B0BR8HPNK2
Volumen 3
(Spanish Edition) Kindle Edition
http://www.amazon.com/dp/B0BR8GYBG7
Volumen 4
Sistema reproductor humano, endocrinología genómica y tipos de cáncer
(Spanish Edition) Kindle Edition
http://www.amazon.com/dp/xxxxxx
Volume’s Date of Publication, Price, Audio
|
Spanish Series D
|
Date of Publication | Spanish Edition Price | English Edition
Price |
Audio |
|
Volumen 1 |
12/28/2022 | 56 | 75 |
no |
|
Volumen 2 |
12/28/2022 | 56 | 2&3
115 |
yes |
|
Volumen 3 |
12/28/2022 | 56 |
no |
|
|
Volumen 4 |
12/xx/2022 | 100 | 135 |
no |
UPDATED on 12/21/2022
Series C, Volume 1 and Volume 2 available on Amazon.com
Serie C: libros electrónicos acerca del cáncer y la oncología(2 book series) Kindle Edition
- Original Volume One: Cancer Biology and Genomics for Disease Diagnosis
On Amazon.com since 8/11/2015
http://www.amazon.com/dp/B013RVYR2K
- NEW GENRE Volume One: Cancer Biology and Genomics for Disease Diagnosis
This volume has the following three parts that are presented in the following order: A, C, B
Audio & Text
- PART A: A1 and A2
- PART C, followed by
- PART B – Graphics & Text, followed by
- Appendix to PART B – Computer Code
Format detailed
>>>> PART A: Audio & Text
PART A.1: The eTOCs in Spanish in Audio format AND
PART A.2: The eTOCs in Bi-lingual format: Spanish and English in Text format
>>>> PART C: The Editorials of the original e-Book in English in Audio format
>>>> PART B: Computer Graphics and English Text
The graphical results of Medical Text Analysis with Machine Learning (ML), Deep Learning (DL) and Natural Language Processing (NLP) algorithms AND the Domain Knowledge Expert (DKE) interpretation of the results in Text format
>>>> Appendix to PART B – Computer Code
Biología y genómica del cáncer para el diagnóstico de la enfermedad (Serie C: libros electrónicos acerca del cáncer y la oncología nº 1) (Spanish Edition) Kindle Edition
Spanish Edition by Stephen J. Williams (Author), Larry H. Bernstein (Author), Dror Nir (Author), Tilda Barliya (Author), Ritu Saxena (Author), Demet Sag (Author), Aviva Lev-Ari (Author), Sudipta Saha (Author), Ziv Raviv (Author), Prabodh Kandala (Author) Format: Kindle Edition
View on Amazon.com
https://www.amazon.com/dp/B0BQHFXKHH
- Original Volume Two: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery
On Amazon.com since 5/18/2017
http://www.amazon.com/dp/B071VQ6YYK
- NEW GENRE Volume Two: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery
Tratamientos contra el cáncer: Metabólicos, genómicos, intervencionistas, inmunoterapia y nanotecnología para la administración de tratamientos
(Spanish Edition) Kindle Edition
Spanish Edition by Larry H. Bernstein (Author), Stephen J. Williams (Author), Tilda Barliya (Author), Aviva Lev-Ari (Author), Demet Sag (Author), Dror Nir (Author), Ziv Raviv (Author), Evelina Cohn (Author), Danut Dragoi (Author) Format: Kindle Edition
View on Amazon.com
https://www.amazon.com/dp/B0BQTM44SM
UPDATED on 12/19/2022
Citation STARTS:
Biología y genómica del cancer para el diagnóstico de la enfermedad (Spanish)
Spanish Edition on Amazon.com
https://www.amazon.com/dp/B0BQHFXKHH
Cancer Biology and Genomics for Disease Diagnosis
(English)
On com since 8/11/2015
http://www.amazon.com/dp/B013RVYR2K
In Spanish Edition,
This volume include graphical results of Medical Text Analysis with Machine Learning (ML), Deep Learning (DL) and Natural Language Processing (NLP) algorithms AND the Domain Knowledge Expert (DKE) interpretation of the results in Text format.
PART B: NLP by Madison Davis, Data preparation by Danielle Smolyar and Premalata Pati, PhD with Interpretation of NLP results by Stephan J. Williams, PhD
Citation ENDS
UPDATED on 12/18/2022
Serie B: Fronteras de la investigación genómica
PRIMER VOLUMEN
EDICIÓN EN ESPAÑOL
Traducción en español
Orientaciones genómicas para la medicina personalizada
View on Amazon.com
https://www.amazon.com/dp/B0BQGZRQ2C
and
Serie B: Fronteras de la investigación genómica
SEGUNDO VOLUMEN
EDICIÓN EN ESPAÑOL
Traducción a español
Lo último en metodologías genómicas para agentes terapéuticos: edición génica, SMP y bioinformática, simulaciones y la ontología del genoma
View on Amazon.com
https://www.amazon.com/dp/B0BQH14CSF
UPDATED on 12/13/2022
The original 6 volumes in Series A: Cardiovascular Diseases in
English Text Edition are found on Amazon.com
For the Series in English text ($515) go to
https://www.amazon.com/dp/B07MVF34ZC/ref=sr_1_1?s=digital-text
12/12/2022 News starts here
The original 6 volumes in Series A: Cardiovascular Diseases in
Spanish Translation Edition are found on Amazon.com
For the Series in Spanish Audio ($385) go to
https://www.amazon.com/gp/product/B0BPR9L1ZX?ref_=dbs_p_pwh_rwt_anx_a_lnk
UPDATED on 12/12/2022
Aviva on Kindle Direct Publishing of
Audio English-Spanish: BioMed e-Series
EDICIÓN EN ESPAÑOL
Indice de contenidos electrónico (IDCe)
AUDIO y TEXTO
https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/
Spanish Edition, Series A: WE ARE on AMAZON.com
Series A, Volume 1:
Puntos de vista acerca del óxido nítrico en los mecanismos patogénicos
https://www.amazon.com/dp/B0BPST4B4N
Series A, Volume 2:
Investigación original cardiovascular: casos de diseño de metodología para la selección de contenidos El arte de la selección de contenidos científicos y médicos
https://www.amazon.com/dp/B0BPRBVLD3
Series A, Volume 3:
Etiología de las enfermedades cardiovasculares: epigenética, genética y genómica
https://www.amazon.com/dp/B0BPR8ZCT3
Series A, Volume 4:
Medicina regenerativa y Medicina traslativa La promesa terapéutica para las enfermedades cardiovasculares
https://www.amazon.com/dp/B0BPRC2WQY
Series A, Volume 5:
Agentes farmacológicos en el tratamiento de las enfermedades cardiovasculares
https://www.amazon.com/dp/B0BPRCZ1QF
Series A, Volume 6:
Cardiología intervencionista para el diagnóstico de enfermedades y cirugía cardíaca para el tratamiento de afecciones
https://www.amazon.com/dp/B0BPRDLFNH
Series A, Volume 1: https://www.amazon.com/dp/B0BPST4B4N
Series A, Volume 2: https://www.amazon.com/dp/B0BPRBVLD3
Series A, Volume 3: https://www.amazon.com/dp/B0BPR8ZCT3
Series A, Volume 4: https://www.amazon.com/dp/B0BPRC2WQY
Series A, Volume 5: https://www.amazon.com/dp/B0BPRCZ1QF
Series A, Volume 6: https://www.amazon.com/dp/B0BPRDLFNH
UPDATED ON 10/20/2022
The factors effecting the IP Valuation of LPBI Group are described in:
- Portfolio of IP Assets
https://pharmaceuticalintelligence.com/portfolio-of-ip-assets/
- 2.0 LPBI is a Very Unique Organization – Section Valuation & Stream of Innovations
https://pharmaceuticalintelligence.com/2021/03/02/2-0-lpbi-is-a-very-unique-organization/
- 2022 Update from LPBI Group
https://pharmaceuticalintelligence.com/2022/02/21/update-from-lpbi-group/
- 2.0 LPBI, Strategy #2: Blockchain Transactions Network Ecosystem
https://pharmaceuticalintelligence.com/blockchain-transactions-network/
- NFT: Redefined Format of IP Assets
https://pharmaceuticalintelligence.com/nft-redefined-format-of-ip-assets/
- Audio English-Spanish: BioMed e-Series
EDICIÓN EN ESPAÑOL
Indice de contenidos electrónico (IDCe)
AUDIO y TEXTO
https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/
UPDATED on 8/30/2022
LPBI Group’s elevator Pitch
LPBI Group’s ventures need to be positioning us as two ventures:
- 1.0 LPBI, 2012 – 2020 – a scientific publisher
- 2.0 LPBI Group, 2021 – 2025 – a software powerhouse with four missions (pipelines)
2022-2023 Elevator Pitch needs to incorporate the following achieved Milestones/accomplishments to date
This Elevator Pitch for 1.0 LPBI, 2012 – 2020 does not include all the PROGRESS accomplished at 2.0 LPBI Group, 2021 – 2025:
Status of 2.0 LPBI Group’s four pipelines is as follows:
Mission #1: NLP (completed):
NEW GENRE NLP
- Genomics Volume Three and
- NEW GENRE Cancer Volume One
both include the Text analysis of the respective original volume processed by NLP algorithms: What are the results and the Domain Knowledge Expert interpretation
- 2.0 LPBI Group’s Mission #1 (Text analysis with AI)
Series B: Genomics
New volume
NEW GENRE Volume Three: Results of Medical Text Analysis with Natural Language Processing (NLP). It is known in 2022, as Genomics Volume Three in NEW GENRE Series B: Frontiers in Genomics Research
Series C: e-Books on Cancer & Oncology NEW GENRE Audio English-Spanish
- Original Volume One: Cancer Biology and Genomics for Disease Diagnosis
On Amazon.com since 8/11/2015
http://www.amazon.com/dp/B013RVYR2K
- NEW GENRE Volume One: Cancer Biology and Genomics for Disease Diagnosis
PART A:
PART A.1: The eTOCs in Spanish in Audio format AND
PART A.2: The eTOCs in Bi-lingual format: Spanish and English in Text format
PART B:
The graphical results of Medical Text Analysis with Machine Learning (ML), Deep Learning (DL) and Natural Language Processing (NLP) algorithms AND the Domain Knowledge Expert (DKE) interpretation of the results in Text format
PART C:
The Editorials of the original e-Book in English in Audio format
Mission #2: Blockchain & NFT – work-in-progress
- Erich is the Lead
- Results of DB Schema Phase 1 will be presented on 9/13 in the Board meeting
Please review
Blockchain Infrastructure we are developing for content monetization [2.0 LPBI Group’s Mission #2]
https://pharmaceuticalintelligence.com/blockchain-transactions-network/
and
NFT minting of our IP [2.0 LPBI Group’s Mission #2]
https://pharmaceuticalintelligence.com/nft-redefined-format-of-ip-assets/
Mission #3: Completion of the Spanish translation of eTOCs for all our 18 BioMed e-Series
- Mission #3 (Spanish Translation and RE-publishing 18 books as NEW GENRE BioMed e-Series:
Audio English-Spanish: BioMed e-Series
EDICIÓN EN ESPAÑOL
Indice de contenidos electrónico (IDCe)
AUDIO y TEXTO
Please review
https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/
Mission #4: Galectins – Drug discovery with software [2.0 LPBI Group’s Mission #4]
– work-in-progress
- Dr. Williams is the Lead
Please review
https://pharmaceuticalintelligence.com/synthetic-biology-in-drug-discovery/
UPDATED on 8/5/2022
The Multimedia new format creates a
NEW GENRE OF SCIENTIFIC BOOK
Each NEW book has three parts:
PART A: The eTOCs in Spanish in Audio format [Spanish Text-To-Spanish Sound]
PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format
PART C: The Editorials of the original e-Books in English in Audio format [English Text-To-English Sound]
https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/
Date of SOUND upload to Amazon, tba
SEE ALL TEXTS in the links, below
Scientific Books e-Series
New Genre: Audio English-Spanish
Spanish Translation performed by
Montero Language Service, Madrid, Spain
Series A: Six volumes – e-Books on Cardiovascular Diseases NEW GENRE Audio English-Spanish
http://www.amazon.com/dp/B00DINFFYC
Original book on com since 6/21/2013
#Spanish #Audio @pharma_BI @AVIVA1950
http://www.amazon.com/dp/B018Q5MCN8
Original Book on Amazon.com since 11/30/2015
#Spanish #Audio @pharma_BI @AVIVA1950
http://www.amazon.com/dp/B018PNHJ84
Original book on Amazon.com since 11/29/2015
#Spanish #Audio @pharma_BI @AVIVA1950
http://www.amazon.com/dp/B019UM909A
Original book on Amazon.com since 12/26/2015
#Spanish #Audio @pharma_BI @AVIVA1950
https://www.amazon.com/dp/B07MGSFDWR
Original book on Amazon.com since 12/23/2018
#Spanish #Audio @pharma_BI @AVIVA1950
https://www.amazon.com/dp/B07MKHDBHF
Original book on Amazon.com since 12/24/2018
#Spanish #Audio @pharma_BI @AVIVA1950
Series B: Frontiers in Genomics Research NEW GENRE Audio English-Spanish
http://www.amazon.com/dp/B018DHBUO6
On Amazon.com since 11/23/2015
- Original Volume One: Genomics Orientations for Personalized Medicine
- NEW GENRE Volume One: Genomics Orientations for Personalized Medicine
#Spanish #Audio @pharma_BI @AVIVA1950
PART A: The eTOCs in Spanish in Audio format
PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format
PART C: The Editorials of the original e-Books in English in Audio format
https://www.amazon.com/dp/B08385KF87
On Amazon.com since 12/28/2019
- Original Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology
- New Genre Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology
#Spanish #Audio @pharma_BI @AVIVA1950
PART A:
A.1: The eTOCs in Spanish in Audio format AND
A.2: The eTOCs in Bi-lingual format: Spanish and English in Text format
PART B: The graphical results of Machine Learning (ML), Deep Learning (DL) and Natural Language Processing (NLP) algorithms AND the Domain Knowledge Expert (DKE) interpretation of the results in Text format – IS ISSUED AS A STANDALONE VOLUME: Volume Three NEW GENRE Volume Three in Series B.
PART C: The Editorials of the original e-Books in English in Audio format
- Volume Three did not exist in the Original BioMed e-Series, Series B: Frontiers in Genomics Research
- During production it was known as PART B of Genomics, Volume Two to be published in the NEW GENRE e-Series B. It was thought to be included in Volume Two. Due to number of plots involved, a standalone volume for NLP Results and Interpretation was born, aka, Volume Three.
- NEW GENRE Volume Three: Results of Medical Text Analysis with Natural Language Processing (NLP). It is known in 2022, as Genomics Volume Three in NEW GENRE Series B: Frontiers in Genomics Research
Series C: e-Books on Cancer & Oncology NEW GENRE Audio English-Spanish
http://www.amazon.com/dp/B013RVYR2K
On Amazon.com since 12/28/2019
- Original Volume One: Cancer Biology and Genomics for Disease Diagnosis
- NEW GENRE Volume One: Cancer Biology and Genomics for Disease Diagnosis
#Spanish #Audio @pharma_BI @AVIVA1950
PART A:
PART A.1: The eTOCs in Spanish in Audio format AND
PART A.2: The eTOCs in Bi-lingual format: Spanish and English in Text format
PART B:
The graphical results of Medical Text Analysis with Machine Learning (ML), Deep Learning (DL) and Natural Language Processing (NLP) algorithms AND the Domain Knowledge Expert (DKE) interpretation of the results in Text format
PART C:
The Editorials of the original e-Book in English in Audio format
http://www.amazon.com/dp/B071VQ6YYK
On Amazon.com since 5/18/2017
- Original Volume Two: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery
- NEW GENRE Volume Two: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery
#Spanish #Audio @pharma_BI @AVIVA1950
PART A: The eTOCs in Spanish in Audio format
PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format
PART C: The Editorials of the original e-Book in English in Audio format
Series D: e-Books on BioMedicine – Metabolomics, Immunology, Infectious Diseases, Reproductive Genomic Endocrinology – NEW GENRE Audio English-Spanish – Volumes 1,2,3,4.
http://www.amazon.com/dp/B012BB0ZF0
On Amazon.com since 7/21/2015
- Original Volume One: Metabolic Genomics & Pharmaceutics
- NEW GENRE Volume One: Metabolic Genomics & Pharmaceutics
#Spanish #Audio @pharma_BI @AVIVA1950
https://www.amazon.com/dp/B075CXHY1B
On Amazon.com since September 4, 2017
- Original Volume Two in the Volume Two and Three combined format: Infectious Diseases and Therapeutics
- NEW GENRE Volume Two: Infectious Diseases and Therapeutics
#Spanish #Audio @pharma_BI @AVIVA1950
https://www.amazon.com/dp/B075CXHY1B
On Amazon.com since September 4, 2017
- Original Volume Three in the Volume Two and Three combined format: The Immune System and Therapeutics
- NEW GENRE Volume Three: The Immune System and Therapeutics
#Spanish #Audio @pharma_BI @AVIVA1950
http://www.amazon.com/dp/B08VTFWVKM
On Amazon.com since February 2, 2021
- Original Volume Four: Human Reproductive System, Genomic Endocrinology and Cancer Types
- NEW GENRE Volume Four: Human Reproductive System, Genomic Endocrinology and Cancer Types
#Spanish #Audio @pharma_BI @AVIVA1950
Series E: Patient-Centered Medicine & Precision Medicine – NEW GENRE Audio English-Spanish
https://www.amazon.com/dp/B076HGB6MZ
On Amazon.com since 10/16/2017
- Original Volume One: The VOICES of Patients, Hospitals CEOs, Health Care Providers, Caregivers and Families: Personal Experience with Critical Care and Invasive Medical Procedures
- NEW GENRE Volume One: The VOICES of Patients, Hospitals CEOs, Health Care Providers, Caregivers and Families: Personal Experience with Critical Care and Invasive Medical Procedures
#Spanish #Audio @pharma_BI @AVIVA1950
https://www.amazon.com/dp/B078313281
On Amazon.com since12/9/2017
- Original Volume Two: Medical Scientific Discoveries for the 21st Century & Interviews with Scientific Leaders
- NEW GENRE Volume Two: Medical Scientific Discoveries for the 21st Century & Interviews with Scientific Leaders
#Spanish #Audio @pharma_BI @AVIVA1950
http://www.amazon.com/dp/B019VH97LU
On Amazon.com since 12/27/2015
- Original Volume Three: Milestones in Physiology & Discoveries in Medicine and Genomics
- NEW GENRE Volume Three: Milestones in Physiology & Discoveries in Medicine and Genomics
#Spanish #Audio @pharma_BI @AVIVA1950
https://www.amazon.com/dp/B078QVDV2W
On Amazon.com since 12/30/2017
- Original Volume Four: Medical 3D BioPrinting – The Revolution in Medicine
- NEW GENRE Volume Four: Medical 3D BioPrinting – The Revolution in Medicine
#Spanish #Audio @pharma_BI @AVIVA1950
HAPPY TO SHARE WITH YOU THIS MILESTONE
UPDATED on 7/22/2022
NEW GENRE Audio English-Spanish – Series E: Patient-Centered Medicine & Precision Medicine
Series E: Patient-Centered Medicine & Precision Medicine – NEW GENRE Audio English-Spanish
>>>>>>
- Original Volume One: The VOICES of Patients, Hospitals CEOs, Health Care Providers, Caregivers and Families: Personal Experience with Critical Care and Invasive Medical Procedures
On Amazon.com since 10/16/2017
https://www.amazon.com/dp/B076HGB6MZ
- NEW GENRE Volume One: The VOICES of Patients, Hospitals CEOs, Health Care Providers, Caregivers and Families: Personal Experience with Critical Care and Invasive Medical Procedures
This volume has the following parts:
PART A: The eTOCs in Spanish in Audio format
PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format
PART C: The Editorials of the original e-Books in English in Audio format
>>>>>>
- Original Volume Two: Medical Scientific Discoveries for the 21st Century & Interviews with Scientific Leaders
On Amazon.com since12/9/2017
https://www.amazon.com/dp/B078313281
- NEW GENRE Volume Two: Medical Scientific Discoveries for the 21st Century & Interviews with Scientific Leaders
This volume has the following three parts:
PART A: The eTOCs in Spanish in Audio format
PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format
PART C: The Editorials of the original e-Books in English in Audio format
>>>>>>
- Original Volume Three: Milestones in Physiology & Discoveries in Medicine and Genomics
On Amazon.com since 12/27/2015
http://www.amazon.com/dp/B019VH97LU
- NEW GENRE Volume Three: Milestones in Physiology & Discoveries in Medicine and Genomics
This volume has the following three parts:
PART A: The eTOCs in Spanish in Audio format
PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format
PART C: The Editorials of the original e-Books in English in Audio format
>>>>>>
- Original Volume Four: Medical 3D BioPrinting – The Revolution in Medicine
On Amazon.com since 12/30/2017
https://www.amazon.com/dp/B078QVDV2W
- NEW GENRE Volume Four: Medical 3D BioPrinting – The Revolution in Medicine
This volume has the following three parts:
PART A: The eTOCs in Spanish in Audio format
PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format
PART C: The Editorials of the original e-Books in English in Audio format
UPDATED on 7/7/2022
Explanation on Results of Medical Text Analysis with Natural Language Processing (NLP) presented in LPBI Group’s NEW GENRE Edition: NLP on Genomics content, standalone volume in Series B and NLP on Cancer content as Part B New Genre Volume 1 in Series C
WORKFLOW for a Eight-Steps Medical Text Analysis Operation using NLP on LPBI Medical and Life Sciences Content
UPDATED on 7/6/2022
Series D: e-Books on BioMedicine – Metabolomics, Immunology, Infectious Diseases, Reproductive Genomic Endocrinology – NEW GENRE Audio English-Spanish – Volumes 1,2,3,4.
>>>
- Original Volume One: Metabolic Genomics & Pharmaceutics
-
NEW GENRE Volume One: Metabolic Genomics & Pharmaceutics
PART A: The eTOCs in Spanish in Audio format
PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format
PART C: The Editorials of the original e-Books in English in Audio format
>>>
- Original Volume Two & Three were published as ONE volume:
The Immune System, Stress Signaling, Infectious Diseases and Therapeutic Implications
- In the NEW GENRE E-SERIES these two volumes are published as two standalone books
>>>
- Original Volume Two in the Volume Two and Three combined format: Infectious Diseases and Therapeutics
-
NEW GENRE Volume Two: Infectious Diseases and Therapeutics
PART A: The eTOCs in Spanish in Audio format
PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format
PART C: The Editorials of the original e-Books in English in Audio format
>>>
- Original Volume Three in the Volume Two and Three combined format: The Immune System and Therapeutics
-
NEW GENRE Volume Three: The Immune System and Therapeutics
PART A: The eTOCs in Spanish in Audio format
PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format
PART C: The Editorials of the original e-Books in English in Audio format
>>>
- Original Volume Four: Human Reproductive System, Genomic Endocrinology and Cancer Types
-
NEW GENRE Volume Four: Human Reproductive System, Genomic Endocrinology and Cancer Types
PART A: The eTOCs in Spanish in Audio format
PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format
PART C: The Editorials of the original e-Books in English in Audio format
UPDATED on 7/2/2022
Series C: e-Books on Cancer & Oncology NEW GENRE Audio English-Spanish
- Original Volume One: Cancer Biology and Genomics for Disease Diagnosis
-
NEW GENRE Volume One: Cancer Biology and Genomics for Disease Diagnosis
PART A:
PART A.1: The eTOCs in Spanish in Audio format AND
PART A.2: The eTOCs in Bi-lingual format: Spanish and English in Text format
PART B: The graphical results of Medical Text Analysis with Machine Learning (ML), Deep Learning (DL) and Natural Language Processing (NLP) algorithms AND the Domain Knowledge Expert (DKE) interpretation of the results in Text format
PART C: The Editorials of the original e-Book in English in Audio format
Subpage:
Cancer, Volume 1: NLP results – 12 Hypergraph Plots and 12 Tree diagram Plots by Madison Davis
- Original Volume Two: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery
-
NEW GENRE Volume Two: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery
PART A: The eTOCs in Spanish in Audio format
PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format
PART C: The Editorials of the original e-Book in English in Audio format
UPDATED on 6/28/2022
Cancer, Volume 1: NLP results – 12 Hypergraph Plots and 12 Tree diagram Plots by Madison Davis
This is a Subpage to
-
NEW GENRE Volume One: Cancer Biology and Genomics for Disease Diagnosis
PART B: The graphical results of Medical Text Analysis with Machine Learning (ML), Deep Learning (DL) and Natural Language Processing (NLP) algorithms AND the Domain Knowledge Expert (DKE) interpretation of the results in Text format
@@@@
This is a Subpage to
UPDATED on 6/23/2022
Series B, NEW GENRE Volumes 1,2 and Results of Medical Text Analysis with NLP
- NEW GENRE Volume One: Genomics Orientations for Personalized Medicine – Series B, Volume 1
- NEW GENRE Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology – Series B, Volume 2
- Genomics Volume 2, Results of Medical Text Analysis with Natural Language Processing (NLP) – PART B in NEW GENRE Series B, Volume 2 This book has a Subpage:
UPDATED on 6/7/2022
Series A, NEW GENRE Volumes 1,2,3,4,5,6
NEW GENRE Volume One: Perspectives on Nitric Oxide in Disease Mechanisms – Series A: Volume 1
NEW GENRE Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation: Series A, Volume 2
NEW GENRE Volume Three: Etiologies of Cardiovascular Diseases – Epigenetics, Genetics and Genomics – Series A, Volume 3
NEW GENRE Volume Four: Therapeutic Promise: Cardiovascular Diseases, Regenerative & Translational Medicine
NEW GENRE Volume Five: Pharmacological Agents in Treatment of Cardiovascular Diseases – Series A, Volume 5
NEW GENRE Volume Six: Interventional Cardiology for Disease Diagnosis and and Cardiac Surgery for Condition Treatment – Series A, Volume 6
UPDATED on 6/6/2022
Audio English-Spanish: BioMed e-Series
- NEW GENRE Audio English-Spanish – Series A: e-Books on Cardiovascular Diseases
- NEW GENRE Audio English-Spanish – Series B: Frontiers in Genomics Research
- NEW GENRE Audio English-Spanish – Series C: e-Books on Cancer & Oncology
- NEW GENRE Audio English-Spanish – Series D: e-Books on BioMedicine – Metabolomics, Immunology, Infectious Diseases, Reproductive Genomic Endocrinology
- NEW GENRE Audio English-Spanish – Series E: Patient-Centered Medicine & Precision Medicine
https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/
UPDATED on 5/24/2022
-
1.0 LPBI IP Asset Class I: Journal Articles by Top Authors
Equity Sharing Calculation: A Scoring System for Author’s (a) Total Articles (single author) and (b) multiple authors)(c) Total Articles Views and (d) Author’s Proportion of own articles views in the Top 14 Journal articles by Views (e) External Citations
Curators: Aviva Lev-Ari, PhD, RN and Stephen J. Williams, PhD
More details are found in
https://pharmaceuticalintelligence.com/2020/12/08/papers-citing-pharmaceuticalintelligence-com/
-
LinkedIn 1st degree connections by Biotech Company Name and by Connections positions
Analytics for e-Reputation based on LinkedIn 1st Degree Connections, +7,500 of LPBI Group’s Founder, 2012-2022: An Intangible Asset – Connections’ Position Seniority & Biotech / Pharma Focus
Author: Aviva Lev-Ari, PhD, RN, Founder of 1.0 LPBI, 2012-2020 & 2.0 LPBI, 2021-2025
and
Data Scientist, Research Assistant III: Tianzuo George Li
UPDATED on 5/7/2022
Tweets at #WMIF2022 by @pharma_BI & @AVIVA1950 and All Retweets of these Tweets – 2022 World Medical Innovation Forum, GENE & CELL THERAPY • MAY 2–4, 2022 • BOSTON
Real Time coverage: Aviva Lev-Ari, PhD, RN
2022 World Medical Innovation Forum, GENE & CELL THERAPY • MAY 2–4, 2022 • BOSTON • IN-PERSON
Lessons on the Frontier of Gene & Cell Therapy – The Disruptive Dozen 12 #GCT Breakthroughs that are revolutionizing Healthcare
UPDATED on 4/25/2022
TODAY, TEN years ago we on 4/25/2012 we published our 1st article
TODAY, 4/25/2022 we have 6,135 articles
TODAY, we have 2,115,903 Views at all time
http://pharmaceuticalintelligence.com
We Celebrate TEN Years of Excellence, LPBI Group: 4/2012 – 4/2022
2022 Update from LPBI Group | Leaders in Pharmaceutical Business Intelligence (LPBI) Group
https://pharmaceuticalintelligence.com/2022/02/21/update-from-lpbi-group/
UPDATED on 4/6/2022
Analytics for e-Reputation based on LinkedIn 1st Degree Connections, +7,500 of LPBI Group’s Founder, 2012-2022: An Intangible Asset – Connections’ Position Seniority & Biotech / Pharma Focus
Author: Aviva Lev-Ari, PhD, RN, Founder of 1.0 LPBI, 2012-2020 & 2.0 LPBI, 2021-2025 and Data Scientist, Research Assistant III: Tianzuo George Li
UPDATED on 3/30/2022
Tweet Collection of 2022 EmTechDigital @MIT, March 29-30, 2022
Tweet Author: Aviva Lev-Ari, PhD, RN
Selective Tweet Retweets for The Technology Review: Aviva Lev-Ari, PhD, RN
UPDATED on 3/21/2022
Agenda overview: EmTech Digital & AI 2022, March 29-30, 2022
https://event.technologyreview.com/emtech-digital-2022/agenda-overview
Aviva will cover EmTech Digital & AI 2022, March 29-30, 2022 in REAL TIME
- on a PRESS PASS from MIT granted today.
Another e-Proceedings and Tweet Collection.
UPDATED on 3/12/2022
2022 Update from LPBI Group
Author & Curator: Aviva Lev-Ari, PhD, RN
2023 Update from LPBI Group
UPDATED on 3/3/2022
We are publishers of PharmaceuticalIntelligence.com
| February 3rd, 2022 | |
| Total # of Scientific Article Views | 2,089.759 |
| Total # of Global Scientific Comments | 7,932 |
| Total # of Categories – Journal Ontology | 743 |
| Total # of Tags | 10,653 |
| Total # of Scientific Articles | 6,112 |
|
Top Author 2/3/2022 |
Total Views by AUTHOR, 2012-2022 |
| 2012pharmaceutical – Aviva Lev-Ari | 508,457 |
| Larryhbern – Dr. Larry | 373,618 |
| Sjwilliamspa – Dr. Williams | 72,513 |
| Tildabarliya – Tilda BarLiya | 69,934 |
| Dr. Sudipta Saha – Dr. Saha | 39,088 |
| Dror Nir – Dr. Nir | 38,314 |
| Demet Sag Ph.D. CRA GCP | 20,030 |
| Ritusaxena – Dr. Saxena | 17,330 |
| Gail S Thornton – PhD(c) | 18,112 |
| Irina Robu, PhD | 10,208 |
UPDATED on 2/8/2022
Announcing LPBI Group’s SCIENCE SIDE – Monthly Virtual Lecture Series on Zoom
Shraga Rottem M.D., D.Sc., Expert, Author, Writer & External Scientific Relations on AI in Medical Applications
Presentation of Several Inventions of AI in Medical Applications (1) Cancer (2) Ultrasound and
Potential Collaboration & funding needs
LECTURE TITLE on 2/15/2022 11AM EST
“Biosensors in Oncology and Prematurity“
the prototype of a novel sensor for the detection of prematurity (nothing to do with uterine contractions) Prematurity is 9.8/100 pregnancies in US and a $22b expense in the first year of life.
LECTURE TITLE on 3/15/2022 11AM EST
AI Based Screening and in Silico Genomic Diagnoses of Congenital Anomalies in Early Pregnancy
UPDATED on 2/7/2022
Announcing New Addition to LPBI Group in dual capacity: EAW & External Scientific Relations:
Shraga Rottem M.D., D.Sc., Expert, Author, Writer & External Scientific Relations on AI in Medical Applications
UPDATED on 12/6/2022
We announce that Pranith Rekala had joined LPBI Group’s Medical Text Analysis with NLP – Mission #1
Pranith Rekala, Research Assistant 2, Medical Text Analysis using NLP (Genomics Content, Project #1; Cancer Content, Project #2) and Molecular Design with Synthetic Biology Software (Project #3).
UPDATED on 1/17/2022
Today we issued a Certificate in Medical Text Analysis to Danielle Smolyar who Joined LPBI Group on 8/15/2020.
We are working now on PART B – NLP for Cancer, Volume 1 – New Genre e-Series
UPDATED on 1/12/2022
There are FOUR points I wish you to take home FROM the five-hour Global Zoom Monthly Board Meeting on
1/11/2022, 11AM EST – 4PM EST
POINT #1:
1 to 7, below represent Frontiers of Compute Technologies in multiple domains where 2.0 LPBI Group had developed and is developing Intellectual Property.
- We completed NLP on 2 major books – 4 are work-in-progress
- Spanish audio and text for eTOCs of 18 books in Medicine
- Books – 140,000 page download
- Blockchain infrastructure – under development – Journal’s Ontology data schema in Knowledge graph in proof of concept stage
- PROTACs with PRosettaC – Galectins Drug Discovery with synthetic biology software
- Auction molecules on the Blockchain IT as NFT
- Auction scientific curations articles on the Blockchain IT as NFT
POINT #2:
We had added to our esteemed group of External Business Relations:
Mr. Luis De La Cruz, Phoenix, AZ – BUSINESS EXECUTIVE, COMMUNITY ACTIVIST AND PHILANTHROPIST
- We will jointly pursuing the following FOUR initiatives that will be mutual beneficial
Exploration of LPBI Group potential contributions to several goals:
INITIATIVE #1:
A Documentary Film on Life Sciences
- We will schedule a BRAINSTORMING JOINT Zoom meeting to kick off IDEAS
- LPBI Group brings to the table the following resources:
- All IP Asset Classes of relevance to the Film https://pharmaceuticalintelligence.com/portfolio-of-ip-assets/
- LPBI Groups Available Podcasts
Type 1: Podcasts about LPBI Group’s Scientists
· Podcast with Dr. Sudipta Saha, PhD, Interview by Gail S. Thornton, PhDc, Narrator’s Voice: Gail S. Thornton, PhDc
· Podcast with Dr. Larry H. Bernstein, MD, FCAP, Interview by Gail S. Thornton, PhDc, Narrator’s Voice: Stephen J. Williams, PhD
· Podcast with Prof. Marcus W. Feldman, PhD, Biology Department, Stanford University, Interview by Gail S. Thornton, PhDc
· Partners in Health and Biz Radio Interview with Aviva Lev-Ari, Ph.D., R.N., Stephen Williams, Ph.D., and Irina Robu, Ph.D., on 5/2019 on topic of 3D Medical BioPrinting Technology: A Revolution in Medicine. Interview organizer: Gail S. Thornton, PhDc
Type 2: Podcasts of LPBI Group’s LIBRARY of 250 INTERVIEWS with Scientific Leaders
Archive for the ‘Interviews with Scientific Leaders’ Category
https://pharmaceuticalintelligence.com/category/interviews-with-scientific-leaders/
INITIATIVE #2:
Use of LPBI Group’s BioMed e-Series for Mission:Brain Foundation
Mr. Luis De La Cruz, is attempting to invite to our February 15, 2022, Dr. Alfredo Quinones, MD
- Dr. Alfredo Quinones MD Mayo Clinic Nuevo – surgeon is the director is this project to share the values of an outreach program for underserved/ disadvantaged communities is the USA.
- Dr Alfredo Quinones-Hinojosa – CNN interview (Short Version)
· Rhoda Goldman Health Lecture: Dr. Alfredo Quinones-Hinojosa
INITIATIVE #3
- Proposal development for presentation to C.S. in Mexico Transfer of Ownership of LPBI Portfolio of IP https://pharmaceuticalintelligence.com/portfolio-of-ip-assets/
ALL Members of our External Business Relations and our Leadership will work on this proposal
INITIATIVE #4
- Spanish speaking countries – Market penetration for LPBI Group’s New Genre Scientific Books – Spanish eTOCs – 18 books in Medicine
A Meeting with Montero and GTO and Mr. De La Cruz
Marketing our NEW GENRE e-Series Books in SPANISH speaking countries
WE will be scheduling a Zoom Meeting with all the Parties
POINT #3:
Dr. Williams developed a methodology on HOW TO write Interpretation for NLP Results
- It was applied on Cancer, Volume 1
- It is been applied on Genomics Volume 2
- It will be applied on Genomics, Volume 1
- It will be applied on Cancer, Volume 2
POINT #4:
- Please Watch the Podcasts by Steve Wolfram on NLP and Blockchain
- Please Watch the Podcasts by Vitalik Buterin on Multiple Blockchains
UPDATED on 1/9/2022
The following sources represent UPDATES on LPBI Group:
Slide deck as of 8/24/2021 – available
I published on our Journal:
• 2021 – A Year in Review
I published on our Journal:
• Portfolio on Intellectual Property Assets:
2012-2020 – Ten IP Assets
2021-2025 – Four IP Assets
I published on our Journal:
2.0 LPBI: A Unique Organization
• Podcast and Text with graphs
- LPBI Group’s multiple technologies include the following:
- We completed NLP on 2 major books of ours – 4 other books are in NLP test analysis process – work-in-progress
- Spanish audio and text for eTOCs of 18 books in Medicine
- Bi-Lingual Spanish-English of eTOCs of these 18 Books
- Editorials of each Book in English Audio
- Above 1,2,3,4 – are included in a New Genre of Scientific Books Launched
- Books in above URL in Blue enjoy – 140,000 page download
- Blockchain infrastructure – under development – Journal’s Ontology data schema in Knowledge graph fluree.com format is in proof of concept stage
- PROTACs with PRosettaC – Galectins Drug Discovery with synthetic biology software
- Auction molecules on the Blockchain IT as NFT
- Auction scientific curations articles on the Blockchain IT as NFT
1,5,7,8,9,10, above represent Frontiers of Compute Technologies in multiple domains where LPBI Group had developed and is developing IP.
UPDATED on 1/3/2022
Mission #1: Medical Text Analysis with Wolfram Language NLP
New Genre BioMed e-Series to include the following Book structure:
PART A: Book electronic Table of Contents (eTOCs) in Spanish: Audio Format and Bi-lingual eTOCs in Spanish-English: Text Format
PART B: (1) Results of Wolfram Language for Biological Sciences – Natural Language Processing (NLP), (2) Appendix: Code used for each plot, and (3) Interpretation of NLP Results by Domain Knowledge Expert
PART C: Original Book’s Editorials excerpt selections in English: Audio Format and Text
Text Analysis with NLP for the entire volume: Cancer Volume 1 was completed on 12/27/2021 by Satwik Sunnam
Cancer Biology & Genomics for Disease Diagnosis. On Amazon.com since 8/11/2015
http://www.amazon.com/dp/B013RVYR2K
Interpretation for NLP Results of Cancer, Volume 1 – is announced as Complete on 1/3/2022. Interpretation done by Dr. Williams
New Genre Book Template for Genomics, Volume 2, PART B: Text Analysis with NLP was completed by Madison Davis on 12/29/2021
Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology On Amazon.com since 12/28/2019
Interpretation for NLP Results of Genomics, Volume 2 – started on 1/3/2022.
- Domain knowledge Expert Interpretation is done by Dr. Williams for Parts 2,3,4,7,8
- Domain knowledge Expert Interpretation is done by Prof. Feldman for Part 5
- Domain knowledge Expert Interpretation is done by Aviva Lev-Ari, PhD, RN for Part 1
UPDATED on 1/2/2022
Medical Text Analysis with Wolfram Machine Learning (ML) and Natural Language Processing (NLP) for LPBI Group’s
Genomics, Volume 2
Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology
https://www.amazon.com/dp/B08385KF87
is as of 1/2/2022 COMPLETE
- The Book’s PART B is 244 pages without the forthcoming Plot interpretations
- without PART A: eTOCs Spanish Audio and Bi-Lingual Text
- without PART C: Editorials – English Text & Audio
- We need a PREFACE for the New Genre of Scientific Books
———————-@@@@@@@@@@@@@———————-
2021
UPDATED on 12/3/2021
UPDATED on 10/22/2021
How LPBI Group plans to use the Spanish Translation of its BioMed e-Series: Cover page of 18 e-Books and electronic Table of Contents of these e-Books?
In November 2021 – I will start to convert the Spanish eTOCs to Sound files and will start to publish
LPBI Group’s
Medical eBooks New Genre Edition !!!!
- Spanish in Audio format,
- Bi-Lingual Text,
- NLP, Results and Domain Knowledge Expert Interpretations, and
- English Editorials in Audio format
Application of LPBI Group’s New Genre Edition of Medical Books:
Each Series: A, B, C, D, E – ONE Volume per Series – 5 volumes in Total
- Series A: Six volumes, All Volumes eTOCs Spanish Audio & Spanish Text & Editorials English Audio
- Series B: Two volumes, All Volumes eTOCs Spanish Audio & Spanish Text & Editorials English Audio
- Series C: Two volumes, All Volumes eTOCs Spanish Audio & Spanish Text & Editorials English Audio
- Series D: Four volumes, All Volumes eTOCs Spanish Audio & Spanish Text & Editorials English Audio
- Series E: Four volumes, All Volumes eTOCs Spanish Audio & Spanish Text & Editorials English Audio
Each Volume: in each Series – 18 volumes in Total
- Part A: Bi-Lingual eTOCs,
- Part B: NLP, Results and Domain Knowledge Expert Interpretations
- Part C: Editorials English Audio
http://www.amazon.com/dp/B00DINFFYC
http://www.amazon.com/dp/B018Q5MCN8
http://www.amazon.com/dp/B018PNHJ84
http://www.amazon.com/dp/B018DHBUO6
http://www.amazon.com/dp/B013RVYR2K
http://www.amazon.com/dp/B012BB0ZF0
http://www.amazon.com/dp/B019UM909A
http://www.amazon.com/dp/B019VH97LU
http://www.amazon.com/dp/B071VQ6YYK
https://www.amazon.com/dp/B075CXHY1B
https://www.amazon.com/dp/B076HGB6MZ
https://www.amazon.com/dp/B078313281
https://www.amazon.com/dp/B078QVDV2W
https://www.amazon.com/dp/B07MGSFDWR
https://www.amazon.com/dp/B07MKHDBHF
https://www.amazon.com/dp/B08385KF87
http://www.amazon.com/dp/B08VTFWVKM
I am so excited about the
Medical eBooks New Genre Edition !!!!
UPDATED on 10/16/2021
It is with the highest OWE that I have issued today
LPBI’s first Cerficicate in Medical Text Analysis for COMPLETION OF 18 Months of Academic Training, the Completion of NLP of an entire book
GENOMICS VOLUME 2
Latest in Genomics Methodologies for Therapeutics:
Gene Editing, NGS & BioInformatics,
Simulations and the Genome Ontology
2019
Volume Two
https://www.amazon.com/dp/B08385KF87
Deep Learning NLP
performed by
MADISON DAVIS
Thank you very much for completion of Genomics Volume 2 – This is a COLLOSAL accomplishment.
Genomics, Volume 2 will be LPBI’s 1st e-Book in
LPBI’s NEW GENRE EDITION of Scientific Books with the following format
- Part A: eTOCs in Spanish AUDIO and Bi-Lingual Spanish and English TEXT – Text Source: ORIGINAL Book
- Part B: Deep Learning NLP by Madison Davis – Graphic Visualization
- Part C: Editorials in English AUDIO – Text Source: ORIGINAL Book
AFTER we finish PART B, above, I am advising Madison:
- to consider to start to work on Synthetic Biology Software for Molecular Design for Galectins
https://pharmaceuticalintelligence.com/synthetic-biology-in-drug-discovery/
- Starting a NEW Internship leading to a New Certificate in Synthetic Biology Software for Molecular Design for Galectins
Detailed description to be found on each Internship page, below
- Medical Text Analysis (Deep Learning NLP)
- IS, IT, CS and Data Science Internship
- Blockchain Knowledge Graph Database Design with Interface to Wolfram NLP
- Finance Internship: Financial Modeling
- Synthetic Biology Software for Drug Design in Glycobiology Internship
- Journalism and Marketing Communications in Pharmaceutical Media
I am encouraging all INTERNS to complete their assignments
- GET Certificate(s)
- Move to Another Internship – ALL ARE TUITION FREE
UPDATED on 10/7/2021
Tweets and Re-Tweets of Tweets by @pharma_BI @AVIVA1950 at 2021 Virtual World Medical Innovation Forum, Mass General Brigham, Gene and Cell Therapy, VIRTUAL May 19–21, 2021, #WMIF2021
UPDATED on 10/4/2021
Tweets and Re-Tweets of Tweets by @pharma_BI @AVIVA1950 at EmTech MIT 2021, #EmTechMIT, Technology Review’s flagship event, September 28-30, 2021
UPDATED on 10/2/2021
LPBI covered in Real Time the Virtual MIT Technology Review’s flagship event, September 28-30, 2021 – EmTech MIT 2021
- EmTech MIT 2021 – Agenda Overview & Speakers: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021
https://event.technologyreview.com/emtech-mit-2021/agenda
- Day 1: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021
- Day 2: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021
- EmTech MIT 2021 – Day 3: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021
UPDATED on 9/27/2021
First day for Satwik Sunnam, Research Assistant 3 in our Team LPBI India is 9/27/2021
Assignment 1: Replacement to Dr. Pati on Cancer Volume 1, Chapters: 7,8,9,10,11,12
- Produce Hypergraph V1 – One for each Chapter for Cancer Volume 1, Chapters: 7,8,9,10,11,12
- Produce Tree Diagram Plots – One for each Chapter for Cancer Volume 1, Chapters: 7,8,9,10,11,12
Assignment 2: Replacement to Ms. Amandeep Kaur on Genomics Volume 1, Chapters: 1-21
- Kaur completed Data preparation Chapters: 1,2,3,4,5 and 21
- Your assignment #2 include:
- Produce Data preparation for Chapters 6 -20
- Produce Deep Learning NLP for Chapters 1 to 21.
UPDATED on 9/22/2021
On 9/20 LPBI had issued the following Certificates:
First Certificate issued in the domain of
Medical Text Analysis with Deep Learning Natural Language Processing
Recipient: Yash Choudhary
On 9/17/2020, LPBI issued the following three Certificates in the domain of
IS, IT and Data Science
for the following Contributions:
Recipients: Abhisar Anand and Srinivas Sriram
for their contribution to IT system solution design for Data Extraction of Article Views
Problem definition:
To extract the views for each of the 6,000+ articles for different time periods. Must be done in a time-efficient manner that retrieves the necessary data for LPBI.
Conceptual solution:
Create a multiple-step process that involves web scraping the data in multiple processes to enhance the speed of the extraction, and use data analysis libraries in Python to format the data in the correct format.
Code Implementation: https://pharmaceuticalintelligence.com/sop-web-stat/
Recipients: Ethan Coomber
For his contributions to Text To Sound conversion of 150 Interviews with Scientific Leaders and for Twitter Analytics on LPBI’s two Twitter handles: @pharma_BI @AVIVA1950
UPDATED ON 9/6/2021
A long weekend ahead of us. Lots of good things to look forward to.
- Labor Day with all its meaning.
- For my culture, the High Holidays.
Blessed to be healthy, very creative and very productive.
What is New at LPBI Group:
- We got this week all our 18 #booksin #medicinetranslated to #spanish
• Cover Page
• electronic Table of Contents - We created the first products using Wolfram #deeplearning
Natural Language Processing #nlp - We made advances regarding launching a #blockchain#knowledge#graphdatabases for our
• +6,080 scientific articles
• 18 Books in Medicine (English and Spanish)
• 100 e-Proceeding oh Top Tier Biotech Conferences
• +6,000 Biological Images - Completed +150 conversion Text to Sound #TTS, I.e., Podcasts of Interviews with Scientific Leaders
- Received the code for our Information System allowing for #data–#analytics#extractionof #articles #views per Year
YES: +2MM Views – #bigdata 3.3 Giga Bytes !!!! - Made strides in further defining our platform for #syntheticbiologyin #drugdiscovery
#biotech #research #language #datascience #translation #ai
So much GOODNESS in one week
UPDATED ON 9/5/2021
Milestones reached on 3Q 2021
- IT & Data Science Internship– LPBI gained the code to run Article Views by any date, 2012 – 2021 – Contributions by Srini and by Abhisar
- Text to Sound: 150 of the 270 Interviews with Scientific Leaders were converted to Podcasts – Contribution by Ethan
- Sign up agreement with SpeechKit– Text to Sound conversion for (a) $204 for 360 podcasts per year (b) Archive bulk conversion 20 cents per Podcast (c) Use API for Spanish Text to Spanish Sound
- ALL 18 BOOKS have a COVER PAGE and an eTOCs in Spanish – Montero competed its Contractand was paid by a Loan Aviva made to LPBI. On 9/1/2021 wired the funds to cover the Invoice.
- Instructions by Madison for all INTERNS on Deep Learning NLPusing Yash’s code – is almost ready
- Proof-of-Concept for Cardiovascular text with Deep Learning NLP is ready by Yash using Adina’s Data preparation
- PowerPoint SLIDE DECK for 2.0 LPBIis Ready – Text by Aviva and PPT by Srini and Abhisar
- Completion of Internship Definition and Certificate Designon 9/2/2021 – Joint Work with Robin and Beth https://pharmaceuticalintelligence.com/certificate-1-year/
- LPBI India is seeking additional Leadership to Dr. Saha and additional INTERNS for (a) Medical Text Analysis using Wolfram Deep Learning NLP and (b) Synthetic Biology Software for Drug Discovery
- Synthetic Biology in Drug Discovery – Mission #4 for LPBI USA is Mission #2 for LPBI India: Updated by Dr. Williams on 8/20/2021. He will present on 9/14/2021. See update https://pharmaceuticalintelligence.com/synthetic-biology-in-drug-discovery/
UPDATED ON 8/31/2021
August 31, 2021 is a GREAT day for both organizations:
- Montero, Language Services, Madrid for COMPLETION of the Spanish Translation of LPBI Group’s EIGHTEEN Books in Medicine: Books Page Cover and electronic Table of Contents (eTOCs) per Volume
- LPBI Group, Boston for having the EIGHTEEN products of the Spanish Translation as agreed upon
This Spanish Translation serves our quest to
- (1) have the opportunity to REACH to the Medical communities in Spanish speaking countries and to Spanish speaking physicians and allied health professionals in the US, and
- (2) having the ability to re-Publish every book and every e-Seriesas a New Genre of Scientific Books in several new formats:
Series A, B, C, D, E – per each Series:
- Never published before as eTOCs of all Volumes in a Series
- Never published before in Spanish: Text or Audio
- Never published before in English Audio
All volumes in each Series – Bi-Lingual and Audio eTOCs
Cover Page and electronic Table of Contents
- Spanish & English Bi-Lingual eTOCs in Text – Today the FINAL products delivered
- Spanish eTOCs Translation in Audio [Text to Sound]
- English eTOCs in Audio [Text to Sound]
Per Volume for each of the 18 Books – New Genre of Scientific Books
- Part A: Bi-Lingual eTOCs: Spanish Audio and English Audio
- Part B: Results of Deep Learning Natural Language Processing with Domain Knowledge Expert Interpretation in [English text work-in-progress] and Spanish text to be translation of this English Text [Future Plan]
- Part C: Book original Editorials in English Audio [Text to Sound]
UPDATED ON 8/16/2021
Proof-of-Concept yielded LPBI’s SOPs on Natural Language Processing – How we will use Deep Learning NOT Statistical NLP !!!!!!!!
- Yash’s code.nb
- Deep learning methods
- 25 keywords
- Code file: code.nb
UPDATED ON 8/7/2021
#1:
LPBI Group announces 5th Academic INTERNSHIP as a Verifiable Certificate Program in Financial Modeling
These are the FOUR ACADEMIC INTERNSHIPS as verifiable Certificate Programs One year or One semester: Volunteer base
- NLP – Medical Text Analysishttps://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/
- Synthetic Biology in Drug Discovery targeting Galectinshttps://pharmaceuticalintelligence.com/synthetic-biology-in-drug-discovery/
- IT Projects and Administration of IP Asset Classes. we developed a Plan for SOPs for LPBI Group’s IT & Data Science Management Projects https://pharmaceuticalintelligence.com/2021/07/11/plan-for-sops-for-lpbi-groups-it-data-science-management-projects/Informations technology & systems of LPBI: Journal, Books, e-Proceedings & Tweet Collections and GALLERY of +6,200 Biological Images. All the platforms: Authoring, publishing and portals. Business analytics for Internet platforms presence: Twitter Analytics +1,100 followers of two handles and LinkedIn ~8,000 1st degree connections of LPBI’s Founder, including +500 CEOs.
- BLOCKCHAIN Architecture Design: Interface to NLP. The powerful aspect is hydrating a knowledge graph with NLP inferences so that they can be used for DISCOVERY. Storing those inferences on a blockchain have the value of committing the NLP inferences to a blockchain for purposes of provenance. However, the very important part is The INFRASTRUCTURE behind BurstIQ which is NOT JUST A BLOCKCHAIN. NLP-Blockchain IT Infrastructure is needed. The NLP inferences are part of a knowledge graph database In BurstIQ case is a LifeGraph – the larger architecture of the system functionality [the voice of Erich G., Chief Architect, LPBI Blockchain Mission #2].
#2:
LPBI and Linguamatics are schedule to meet with
- LPBI’s and Linguamatics’ potential NEW two clients:
- Director of Research at an HMO &
- COO/CEO of a Healthcare INSURER on
- August 18, 2021 at 3PM EST
#3:
LPBI’s GLOBAL Monthly Zoom Meeting is on August 10, 2021 at11AM EST to 4PM EST – Please ATTEND
Presentations by
- Williams
- ALL 2021 SUMMER INTERNS
- Aviva
- External Presenter TBA
AGENDA for August 10, 2021 at 11AM EST to 4PM EST
Link sent on 8/9 at 5PM and on Link REMINDER on 8/10 at 9AM
https://pharmaceuticalintelligence.com/calendar/
UPDATED ON 8/3/2021
LPBI Team in LPBI India include: 3,4,6,7,8,10,11
UPDATED ON 7/26/2021
We are excited to have new Interns coming onboard with inquisitive minds and motivation to learn new skills and invest in their careers by Experientional learning methods.
LPBI Group runs FOUR MAJOR INTERNSHIPS: Volunteer base
- NLP – Medical Text Analysis
- Synthetic Biology in Drug Discovery targeting Galectins
- IT Project and Administration of IP Asset Classes: Journal, Books, e-Proceedings & Tweet Collections and GALLERY of +6,200 Biological Images
- BLOCKCHAIN Architecture design: Interface of NLP. The powerful aspect is hydrating a knowledge graph with NLP inferences so that they can be used for DISCOVERY.
Storing those inferences on a blockchain have the value of committing the NLP inferences to a blockchain for purposes of provenance. However, the very important part is The INFRASTRUCTURE behind BurstIQ which is NOT JUST A BLOCKCHAIN.
- NLP-Blockchain IT Infrastructure is needed.
- The NLP inferences are part of a graph database
- In BurstIQ case is a LifeGraph – the larger architecture of the system functionality.
LPBI has you and your education goals in mind:
- We Offer esteemed Affiliation, Mentorship by Scientists
- NEW skills development in NLP, ML, AI applications to Medical Text Analysis
- Skills in Synthetic Biology for Drug Discovery
- References and Resume paragraph on accomplishments and goals during the INTERNSHIP
- Opportunity to contribute to Publications and Podcasting
- Explorations of opportunities in Life Sciences in the US
UPDATED ON 7/26/2021
LPBI’s VALUATION is the stream of INNOVATIONS to date while being DEBT free:
- 4/2012 – LPBI is the Launcher of Scientific Curation Methodology for the e-Scientific Publishing industry https://pharmaceuticalintelligence.com/As late as in 2016 no big publisher, i.e., Elsevier, John Wiley had curation-based publications: Journal, Books, e-Proceedings, Gallery of +6,000 Biological Images as an IP asset class
- At LPBI, Curation of scientific findings was performed in +6,000 articles with +2MM e-Views by Global e-Readers
- 6/2013 – LPBI was the Publisher of the 1ste-book in Medicine in Kindle Store on the Life Sciences & Medicine Shelf – Upload to this shelf by Amazon.com
- 2/2021 – Completion of the 18 volumes, BioMed e-Series in five Specialties in Medicine
- On Amazon.com on 7/2021 – e-books in Medicine enjoy +128,100 PAGE DOWNLOADS – the ONE and ONLY publisher in that range of page downloads
- LPBI launched NLP in 1/2020. Linguamatics/IQVIA performed NLP on 33 articles and 20 Biological Images. RESULTS: +670 entity relations DISCOVERED by Linguamatics and unknown to Pharma and to Insurers, entity relations between:
- Gene-Disease
- Gene-Drug
- Disease-Drug
- These results were presented to a Healthcare Insurer, SLC, UT on 7/13/2021
- LPBI and BurstIQ are architecting NOW the first NLP-Blockchain IT infrastructure in existence
- Linguamatics did not hear of Blockchain and BurstIQ did not have a request for NLP – LPBI PUT THESE TWO TECHNOLOGIES AND PARTIES TOGETHER
- On 7/19/2021 – LPBI had launched LPBI India for Synthetic Biology for Drug Discovery targeting Galectins – Collaboration with Dr. Raphael Nir, ABI Lab and SBH Sciences, Inc., Natick, MA
- On 7/25/2021 – LPBI announced it will have the NEWLY to be published BioMed e-Books As ANEW Publishing GENRE of SCIENTIFIC BOOKS
- Bi-Lingual eTOCs, English & Spanish with Montero Language Services, Madrid and Content promotion by GTO, Madrid
- NLPs results of Medical Text Analysis with domain knowledge expert Interpretations in Foreign Languages and Audio: Spanish and other
- Original English Book – Only Editorials(Preface, Introductions, Summaries and Epilogue] because the Bi-Lingual part is the eTOCs of the e-Book
- New architecture of MULTIMEDIA SCIENTIFIC e-Books
- Based on the Price List for LPBI 1.0 digital products and of LPBI 2.0 – NLP Products https://pharmaceuticalintelligence.com/2020/11/16/data-architecture-for-blockchain-deployment-of-digital-assets-lpbi-ip-asset-classes-iiiiii/we are building
- Scenarios of Product Mix for $500,000 B2B engagements with NLP scaling up alliances: Alliances are Labor component and LPBI is Materials – 25% on top paid by the B2B customer
- B2C on Blockchain will use the Price List.
UPDATED ON 7/19/2021
Official launch of LPBI India – Zoom meeting
On July 19, 2021 at 11AM EST
UPDATED AGENDA
|
Member Name |
Geographical region in India Or Place of Birth in India if now outside of India |
Distance from New Delhi |
LANGUAGES |
|
Dr (Lt Col) Vivek Lal |
Ambuja Nagar, Kodinar (Sasan-Gir) Gujarat. |
1300 kms |
English, Hindi |
|
Yash Choudhary |
Dewas (Madhya Pradesh) |
800 kms |
English, Hindi |
|
Dr. Premalata Pati |
Bhubaneswar, Odisha |
1764 kms |
English, Hindi, Odia |
|
Dr. Sudipta Saha |
Kolkata, West Bengal |
1500 kms |
English, Hindi, Bengali |
|
Dr. Ajay Gupta |
Place of birth: New Delhi |
0 |
English, Hindi |
|
Amandeep Kaur |
Kolkata, West Bengal |
1500 kms |
English, Hindi, Punjabi, Bengali |
|
Indraneel Ghosh |
Vadodara, Gujarat |
1025 kms |
English, Hindi, Bengali, Marathi, Gujarati |
|
Aditya Bahl |
Lucknow, UP |
500 |
English, Hindi, Punjabi |
|
Srinivas Sriram |
Place of Birth: Chennai, Tamil Nadu |
2,187 kms |
English, Tamil |
|
Abhisar Anand |
Place of Birth: Muzaffarpur, Bihar |
1,042 kms |
English, Hindi |
ANNOUNCEMENT
Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston, MA
is Launching LPBI India on 7/19/2021
LPBI India Official Launch
on Zoom on July 19, 2021 at 11AM EST
- I wish to invite you to attend this Zoom meeting using the Zoom Link, above
LPBI India LAUNCH
is on Monday July 19, 2021 at 11AM EST
Aviva – Founder 1.0 LPBI and 2.0 LPBI
- Justifying the Launch of LPBI India todayis the Interaction between LPBI USAand LPBI India which is taking place multiple times every day
- Senior level executive talent in India expressed interest to JOIN LPBI USA while living in India
- It was Dr. Lal and Dr. Ghosh interest in joining LPBI USA that impacted Aviva’s Decision toward the Launch of LPBI India: Leadership + Professional Staff
- Interactions among all members across Indiais mostly encouraged
- We are preparing a MAP with all the locations in India of our VIRTUAL organization
- We are a community of inclusion and excellence challenging and aspiring for expression and growth of the best of our abilities without borders and/or pre-determinants of any kind: age, race, religion or gender
- Interactions with Alumni of LPBI USAis mostly encouraged – we are very proud of each of you,
Congratulatory Remarks, each presenter from their own perspective:
- LPBI USA Board member, Marc W. Feldman, Stanford University [7/18/2021 – Medical Emergency] <<< – WE WISH YOU SPEEDY RECOVERY, next Global Zoom on August 10, 2021 – Congratulatory remarks will be delivered
- LPBI USA Board member, Stephen J. Williams,Temple University
- Ajay Gupta of UC, Irvine, LPBI USA, External Scientific Relations
- Aditya Bahl, MBA, LPBI USA, External Business Relationsto LPBI USA since 1/2020. Mr. Bahl is ex-Novastis and ex-J&J, the Founding Director at RAS Life Science Solutions, based in Frankfurt, Germany
- Raphael Nir, Founder, ABI Lab and President, SBH, Inc in Natick, MA – We will have in 4Q’2021 a JOINTmeeting dedicated to Mission #2, below
Mission #1:
Medical Text Analysis with Natural Language Processing (NLP), Machine Learning (ML), Artificial Intelligence (AI)
The Medical Text includes FOUR corpuses of content created by the Team at LPBI USA since 4/2012:
- Scientific Curation Articles published in our Open Access Journal http://pharmaceuticalintelligence.com
N = +6,070, Views = +2Million, with an ontology of +730 categories of Research in the Life Sciences, Medicine, Pharmaceutics and Healthcare
- 18 e-Books in Medicine https://lnkd.in/ekWGNqA
128,000 page download on Amazon.com – Cover Pages and electronic Table of Contents (eTOCs) of the 18 books are been translated to Spanish in Madrid, now
- 100 e-Proceedings of Global Medical and Biotech Conferences generated in Real Time, 2013 – 2021 https://pharmaceuticalintelligence.com/press-coverage/part-three-conference-eproceedings-deliverables-social-media-analytics/
- +6,200 Biological Images with text legend in use by the +6,000 articles – in the Media Galleryof LPBI on WordPress.com cloud. Mission #1 has increased the number of Biological images from 5,100 to +6,200
At LPBI India, been considered for the Leadership function for Mission #1: Dr. Vivek Lal, MD
STRATEGIC PLAN for Mission #1
For scaling up the Text Analysis of these 3.3 Giga Bytes of data we are in alliance with Linguamatics/IQVIA, London https://www.linguamatics.com/what-text-mining-text-analytics-and-natural-language-processing
- We jointly presented their NLP results on our content in oncology to a Top HMO/Healthcare Insurer in UT on July 13, 2021. We are invited for additional meetings with both organizations: the HMO and the Healthcare Insurer
- LPBI USA developed a ten-phase Protocol for our own content been subjected to Medical Text Analysis with NLP, ML, AI using Wolfram language for BioSciences
- LPBI India will be involved in all of the ten-phase Protocol in using NLP, ML, AI
- LPBI is in alliance with BurstIQ, Denver, CO https://www.burstiq.com/for Blockchain design for a Transactions Network for Content monetization: B2B and B2C. That process involve Indexing and data migration. LPBI India will play a role in these tasks as well
Mission #2:
Applications of Synthetic Biology Software to Galectins for design of new drug molecules.
- Collaboration with Raphael Nir of ABI Lab and SBH, Inc in Natick, MA. We will have in 4Q’2021 a dedicated meeting on Mission #2.
- LPBI India will play a role in these tasks, please review:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877766/
- LPBI USA has interest in Synthetic Biology Software for Drug Discoveryand has two scientists with expertise in Galectins as therapeutic targets
- Scientists love Synthetic Biology – designing drug molecules using Software – igem.org
A repository of open source software tools.
Community driven data exchange standards.
Specific software frameworks built explicitly for synthetic biology.
- LPBI USA will have a DropBox Folder with all the Synthetic Biology Software accessible toLPBI India
- Mentorship and training will be offered by LPBI USA
At LPBI India, been considered for the Leadership function for Mission #2: Dr. Indraneel Ghosh, PhD
STRATEGIC PLAN for Mission #2
- We will have in 4Q’2021 a JOINT meeting between LPBI USA, LPBI India with Raphael Nir of ABI Lab and SBH, Inc in Natick, MA on Mission #2.
- A collaboration between Dr. Ghosh and Dr. Nir is expected
AGENDA
Zoom of LPBI INDIA Launch on Monday July 19, 2021 at 11AM EST
PRESENTATIONS
- Stephen J. Williams,LPBI USA, Chief Scientific Officer and Board Member is with LPBI USA since 9/2012 will have presentations
- Aviva will have presentations
Senior Level at LPBI India:
- LPBI India TEAM Members BIO Presentations: Each of the members of LPBI Indiawill present their BIO in <5 minutes, starting with
Dr. Sudipta Saha, PhD Prof. at Amity University, New Delhi. Dr. Saha is with LPBI USA since 9/2012, Expert, Author and Co-Editor
http://www.amazon.com/dp/B08VTFWVKM
Available on Amazon.com since 2/2/2021
https://www.amazon.com/dp/B075CXHY1B
On Amazon.com since September 4, 2017
Dr. Vivek Lal, MD, COO, Ambujanagar Multi-specialty Hospital, Ambujanagar, Dist. Gir-Somnath, Gujarat, India.
- Paper collaboration with Dr. Justin D. Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN on 9/2013, article has ~15,000 e-Readers https://pharmaceuticalintelligence.com/2013/09/23/do-novel-anticoagulants-affect-the-ptinr-the-cases-of-xarelto-rivaroxaban-and-pradaxa-dabigatran/
Dr. Indraneel Ghosh, PhD – Weizmann Institute PhD, 2000-2007, Hebrew speaker
- CV on LPBI USA Website – Work-in-Progress
Dr. Ajay Gupta of UC, Irvine, Scientific Advisor to LPBI USA, frequent presentation on LPBI’s SCIENCE SIDE – Global Monthly Zoom
- Ten Minuteson on Clinical Trials for RAMATROBAN – Opportunities for Collaboration between His Company in USA & LPBI India, Dr. Lal’s Hospital and other Hospitals in India
Ramatroban is a thromboxane receptor antagonist. It is also a DP₂ receptor antagonist. It is indicated for the treatment of coronary artery disease. It has also been used for the treatment of asthma. Wikipedia
ChemSpider ID: 110413
Molar mass: 416.47 g·mol−1
Formula: C21H21FN2O4S
Members of Technical Staff (MTS) at LPBI India & LPBI USA:
- All LPBI India MTS currently working on Mission #1 and
- All LPBI USA MTScurrently working on IT/Data Science Projects
- will be invited to considered Mission #2.
- An Up-to-date CV in Biological SciencesREQUIRES DEMONSTRATION of making contributions with mentorship in both areas: Mission #1 and Mission #2
LPBI India and LPBI USA MTS – BIO Presentations: PostDocs, Masters and Students will present their Bios in <4 minutes:
- Pati,PostDoc. NLP – One year Academic Training
- Kaur, MSc. NLP – One year Academic Training
- Choudhary,Student IITK – Summent intern, 6/15/ – 8/15/2021
- Sriram,Student Westford Academy, MA – Born in India, thus, LPBI USA & LPBI India
- Anand, Student Westford Academy, MA – Born in India, thus, LPBI USA & LPBI India
- Ethan Coomber, Middlebury College, VT – Research Assistant 3, Text to Audio Conversion and Twitter Analytics
- Vaishnavee Joshi, MSc – Joining LPBI India on 8/15/2021
Alumni of LPBI USA are invited to join us on Monday, July 19, 2021, 11AM EST
- Probodh Kandala, PhD, Regulatory Affairs Manager @ IQVIA Biotech; Drug Development Leader, Expert, Author, Writer with scientific reporting articlesin multiple of LPBI e-Books, chiefly Cancer and Immunology
- Ritu Saxena, PhD, Astellas Pharma US, Co-Editor, LPBI’s Series C, Volume 1 http://www.amazon.com/dp/B013RVYR2K
- Aviral Vatsa, MD, NHS Education for Scotland, Co-Editor,LPBI’s Series A, Volume 1 http://www.amazon.com/dp/B00DINFFYC
- Aashir Awan, Research Scientist, Bristol Myers Squibb, Expert, Author, Writer (EAW) for PharmaceuticalIntelligence.com
- Anamika Sarkar,Regeneron, EAW at LPBI 2014-2016
Alumni of LPBI USA: Please catch up with us, we thank you for your contributions made to LPBI USA
- Please review our portfolio of Intellectual property of 10 Asset Classes in 2021 https://pharmaceuticalintelligence.com/2019-vista/
- Please review our six strategies for 2021-2025https://pharmaceuticalintelligence.com/vision/
@@@@@@@@ ALL NEED TO PLAN TO ATTEND 7/21, 2021 – LPBI USA – BUSINESS SIDE
UPDATED ON 7/5/2021
ANNOUNCEMENT of NEW SUMMER INTERN in Medical Text Analysis with NLP – Cardiovascular Content – 2021 Summer Internship in NLP – LPBI India
Yash Choudhary, Research Assistant 3
UPDATED ON 6/20/2021
ANNOUNCEMENT of NEW SUMMER INTERN
Ethan Coomber, Research Assistant III, Data Science and Podcast Library Development
UPDATED ON 6/16/2021
ANNOUNCEMENT of TWO NEW SUMMER INTERNS who also plan to start in 9/2021 the LPBI 2021-2022 Academic Training in NLP for Medical Text Analysis
Abhisar Anand, Research Assistant I
Srinivas Sriram, Research Assistant I
UPDATED ON 5/17/2021
LPBI management wants you to be PROUD about
- The Spanish Translation 18 volumes (Cover Pages, eTOCs all books) – Alliance with Montero Language Services, Madrid, Spainand their’s Marketing Communication Agency for
1.1 Plans for Content Promotion in Spanish Speaking Countries
1.2 Other Marketing Communications needs of 2.0 LPBI
- NLP plan for IP Asset Classes I,II, III, V – Consideration of Alliance with Linguamatics/IQVIAfor Indexing of +6,000 articles
- Blockchain Transaction Network for Content monetization system design for Digital Store in a Healthcare Digital Marketplace: B2B, B2C – Collaboration with BurstIQ
- Insurer Contactand Proof-of-Concept READY for joint Presentation with Linguamatics/IQVIA
- IB in NYC preparing Proposal for LPBI becoming their Client
- Working with few Sources to identify C-Suite new Members
- New Management
- New Ownership
- New Company – incorporation as ‘C’
UPDATED ON 5/5/2021
One Pager for 2.0 LPBI Group
For the first time in the ten years of our private ownership, the opportunity to acquire the Inventor of Scientific curation has become a reality, Available for Transfer of ownership.
You can own a portfolio of Intellectual Property Assets that commands ~2MM e-Readers and offers +6,000 of the best interpretive articles in five specialties of Medicine and Life Sciences. Pages of our 18 books have been downloaded ~135,000 times and over 100 of the top biotech and medical conferences were covered in real time and recorded in writing and Tweets. New strategies in AI and Blockchain are now applied on LPBI’s content for INSIGHT searches and pattern recognition by automated Machine Learning algorithms for use in drug discovery and drug repurposing. All of LPBI’s content was created by our Experts, Authors, Writers (EAWs).
- Bold vision for the coming five years includes: All content will be converted by Machine Learning algorithms to search for all hyper-graphs and their expression in WordClouds.
- From text we will convert content to Audio. From English Text we will translate to foreign languages like Japanese, Spanish and Russian.
- From Open Access we will transition to Blockchain transaction networks.
- From Digital Cloud-based biographies we will create audio and video Podcasts
- From a sole owner-operator status we will transition to Joint-Ventures to M&A and Partnerships
Our Transformational transition is two dimensional:
- Our deep expertise and innovations in media platforms and content creation will have new directions: we will focus on other Countries (x,y,z) and Geographical regions: i.e., EU and South-East Asia. Currently the Table of Contents of 18 books is being translated into Spanish for the 22 Countries speaking Spanish.
- Our created content will become the basis of our content mining and the subject of managed computerized text analysis under supervised learning guided by our own team of experts.
We are fundamentally a media system integrator, platform developer and platform customizer; an innovative and creative scientific content creator. We function as a fully vertically integrated BioMed creator and generator of knowledge for health information markets via our own Journal articles, BioMed e-Series of Books, Conference e-Proceedings, Podcasts, and additional five strategies https://pharmaceuticalintelligence.com/vision/
5/5/2021
LPBI Group’s Organizational Chart was updated on 5/5/2021
4/24/2021
REMINDER of important articles in our repository
e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point
Thriving at the Survival Calls during Careers in the Digital Age – An AGE like no Other, also known as, DIGITAL. Author and Curator: Aviva Lev-Ari, PhD, RN
Pioneering implementations of analytics to business decision making: contributions to domain knowledge conceptualization, research design, methodology development, data modeling and statistical data analysis: Aviva Lev-Ari, UCB, PhD’83; HUJI MA’76
4/14/2021
Mechanism of thrombosis with AstraZeneca and J & J vaccines: Expert Opinion by Kate Chander Chiang & Ajay Gupta, MD
2/26/2021
2021 Virtual World Medical Innovation Forum, Mass General Brigham, Gene and Cell Therapy, VIRTUAL May 19–21, 2021
Real Time coverage: Aviva Lev-Ari, PhD, RN
2/16/2021
Announcing two new members of the Medical Text Analysis with Machine Learning
Premalata Pati, PhD, PostDoc in Biological Sciences, Medical Text Analysis with Machine Learning
Amandeep Kaur, BSc., MSc. (exp. 5/2021) – Research Associate 2, Medical Text Analysis and IT Infrastructure Python Coder
2/12/2021
Need for Global Response to SARS-CoV-2 Viral Variants
Reporter: Aviva Lev-Ari, PhD, RN
Rise of a trio of mutated viruses hints at an increase in transmissibility, speeding the virus’ leaps from one host to the next
Reporter: Aviva Lev-Ari, PhD, RN
2/8/2021
LIVE – 50th Annual Lewis S. Rosenstiel Award to Katalin Karikó and Drew Weissman for work on messenger RNA, modification of Nucleic Acids applied in the development of COVID-19 Vaccines
Reporter & Real Time Coverage on 2/8/2021:
2/5/2021
Today Series D: Volume 4, LPBI’s #18 Volume is LIVE
Series D: e-Books on BioMedicine – Metabolomics, Immunology, Infectious Diseases and Endocrinology
VOLUME 1: Metabolic Genomics and Pharmaceutics.
(Series D: BioMedicine & Immunology) Kindle Edition
On Amazon.com since 7/21/2015
http://www.amazon.com/dp/B012BB0ZF0
VOLUME 2: Infectious Diseases and Therapeutics
and
VOLUME 3: The Immune System and Therapeutics
(Series D: BioMedicine & Immunology) Kindle Edition. On Amazon.com since September 4, 2017
https://www.amazon.com/dp/B075CXHY1B
VOLUME 4: Human Reproductive System, Genomic Endocrinology and Cancer Types
(Series D: BioMedicine & Immunology) Kindle Edition.
On Amazon.com since February 2, 2021
http://www.amazon.com/dp/B08VTFWVKM
2/3/2021
Check our podcasts
-
Podcast with Dr. Sudipta Saha, PhD, Interview by Gail S. Thornton, PhDc, Narrator’s Voice: Gail S. Thornton, PhDc
-
Podcast with Dr. Larry H. Bernstein, MD, FCAP, Interview by Gail S. Thornton, PhDc, Narrator’s Voice: Stephen J. Williams, PhD
-
Podcast with Prof. Marcus W. Feldman, PhD, Biology Department, Stanford University, Interview by Gail S. Thornton, PhDc
-
Partners in Health and Biz Radio Interview with Aviva Lev-Ari, Ph.D., R.N., Stephen Williams, Ph.D., and Irina Robu, Ph.D., on 5/2019 on topic of 3D Medical BioPrinting Technology: A Revolution in Medicine. Interview organizer: Gail S. Thornton, PhDc
2/1/2021
Milestone achieved today:
February 1, 2021 – We Celebrate 1,924,400 e-Readers, 6,000 Scientific Journal Articles, 7,525 Scientific Comments, A Journal Ontology of 728 Medical
Thought on the transition
One Possible Strategy for an Acquisition is via a SPAC
1/8/2021
PharmaceuticalIntelligence.com Journal – Projecting the Annual Rate of Article Views
Hanoch Lev-Ari, PhD and Aviva Lev-Ari, PhD, RN
Total number of articles viewed in any given year depends on:
- The overall Average Article-Viewing Profile (AAVP)
- The number of articles published in the year of interest, and in each one of the preceding years.
In statistics, the article viewing process is known as a “marked point process”: the time-instants of article publication are the events described by the point process, while the “mark” is the subsequent process of viewing each particular article, ongoing from the moment of publication into the future over many years. The article viewing process is assumed to be statistically-independent from the publication time-instants.
1/6/2021
2.0 LPBI Team Welcomes to our Medical Text Analysis Team
Amandeep Kaur, BSc., MSc. (exp. 5/2021) – Research Associate 2, Medical Text Analysis and IT Infrastructure Python Coder
REUTERS NEXT (Jan 11-14) kicks off 2021 by gathering global leaders and forward thinkers to reimagine solutions to the challenges the new year brings
Reporter: Aviva Lev-Ari, PhD, RN
1/3/2021
Data Architecture for Blockchain Deployment of Digital Assets: LPBI IP Asset Classes I,II,III,V
Author: Aviva Lev-Ari, PhD, RN
Announcing Strategic Transition from 1.0 LPBI to 2.0 LPBI on 1/1/2021: New Management, Marketing Communication and New Scientific/Technical Opportunities
Author: Aviva Lev-Ari, PhD, RN
1/1/2021
Announcing Strategic Transition from 1.0 LPBI to 2.0 LPBI on 1/1/2021: New Management, Marketing Communication and New Scientific/Technical Opportunities
Author: Aviva Lev-Ari, PhD, RN
For your New Opportunity in 2021:
- Management,
- MarkComm and
- Scientific/Technical
CONTACT
Director & Founder
e-Mail: avivalev-ari@alum.berkeley.edu
(M) 617-775-0451
DESCRIPTION
https://pharmaceuticalintelligence.com/vision/
Announcement
Strategic Transition from 1.0 LPBI to 2.0 LPBI on
1/1/2021
We have transitioned from
- 1.0 LPBI was an electronic Scientific Publisher, 2012 – 2020
to
- 2.0 LPBI a Medical Text Analysis (NLP-ML-AI) – SaaS and Content Monetization (Blockchain) – BaaS. A new company profile, 2021 – 2025
Our New NEEDS in Business Development and M&A – Pursue with results:
- Equity Sharing based
Opportunities Map in the Acquisition Arena
Our New NEEDS in Marketing Communication, Media & PR – Produce new Digital mediums
- Equity Sharing based
- The Announcement of 2.0 LPBI Launch
- NEW Website for 2.0 – Initiative #2
- Podcast – Strategy #4 – we wish to publish 2 Podcasts per quarter
- Planning Advertisement for Amazon Books using Amazon Advertising
- NEW documentation on Strategy #2 – Monetization of Journal Articles
- NEW documentation on Strategy #2 – Monetization of other IP Asset Classes
- NEW documentation on Strategy #1, #3, #6
- Reporting on developments in Strategy #5: Joint Ventures & Partnership
Our New Scientific/Technical Opportunities in Natural Language Processing (NLP), Machine Learning (ML) and Artificial Intelligence (AI)
Seeking 10 Students INTERNS for a major Medical Text Analysis using NLP, ML, AI
This is a ONE year VIRTUAL STUDENT INTERNSHIP for
- Computer Science & Biological Sciences or
- PreMed students
- PostDocs will develop the interpretation for the hyper-graphs
This internship is not fee for service – but voluntary and offers
- Mentorship by Scientists
- Letter of recommendation
- Opportunity to publish with lead authors
- Hands on experience with software
- Opportunities to present in corporate business meetings
- Scientific Career guidance
- Access to contacts in Academe and Industry
DESCRIPTION
https://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
FrasonKalapurackal
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
zraviv06
zs22